Takeda America Holdings Inc., a wholly-owned subsidiary of Takeda, and Intellikine, a privately-held company focused on the discovery and development of innovative, small molecule drugs, have entered into an agreement for Takeda America Holdings to acquire Intellikine.
Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings Inc. will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.
Intellikine’s most advanced drug candidate, INK128, a novel mTORC1/2 inhibitor, has generated encouraging data in multiple Phase 1 studies and is expected to enter Phase 2 studies in 2012. INK1117, a novel and selective inhibitor of the PI3K? isoform, entered human clinical testing in September 2011.
The Takeda Oncology Company, Takeda’s business unit responsible for global oncology strategy and development, will have global development responsibility for INK128 and INK1117.
Release Date: Dec. 20, 2011
Source: Takeda America Holdings Inc.
